No Data
Express News | Zhejiang Huahai Pharmaceutical: Subsidiary HB56 injection granted clinical trial approval in New Zealand.
Aotec Pharma (688606) 2024 Third Quarterly Report Review: Small but excellent POCT leader, continuous improvement in operational situation.
Key Investment Events: On October 30, 2024, the company released its third-quarter report for 2024. In the third quarter alone, the company achieved revenue of 0.222 billion yuan, a year-on-year increase of 28.72%, with a net income attributable to shareholders of 0.74.
Aotai Biotech: Third quarter report 2024
Third Quarter Report 2024
Aotec Biology (688606.SH) released its performance for the first three quarters, with net income of 0.198 billion yuan, a year-on-year increase of 94.48%.
Aotec Pharmaceuticals (688606.SH) disclosed the third quarter report for 2024, achieving revenue of 6....
Ou Tai Biology (688606): Layout of overseas markets. Small and beautiful POCT leader.
Investment highlights focus on POCT, strong international market influence: Autobio focuses on the research, development, production, and sales of in vitro diagnostic reagents. The main product line includes infectious disease testing, drug abuse testing, women's health testing, etc., and has already been present globally.
No Data
No Data